» Articles » PMID: 31091175

Trends in Complementary and Alternative Medicine Use Among Patients with Prostate Cancer

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2019 May 16
PMID 31091175
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We explored the prevalence and trends of self-reported complementary and alternative medicine use among patients with prostate cancer using CaPSURE™ (Cancer of the Prostate Strategic Urologic Research Endeavor).

Materials And Methods: A total of 7,989 CaPSURE participants completed questionnaires between 1996 and 2016 on the use of nearly 70 complementary and alternative medicine types. Participants were defined as users if they indicated that they had ever used complementary and alternative medicines. To evaluate trends among 7,696 patients with newly diagnosed prostate cancer we considered complementary and alternative medicine use within 24 months of diagnosis and calculated the percent change in complementary and alternative medicine use between groups defined by the year of diagnosis.

Results: Of patients with prostate cancer 56% reported complementary and alternative medicine use on at least 1 questionnaire. Multivitamin and omega-3 fatty acid use was common at 40% and 24% of patients, respectively. Compared to nonusers greater proportions of complementary and alternative medicine users were college educated, had a higher household income and lived in the West and Midwest. Median prostate specific antigen at diagnosis was 5.8 (IQR 4.4-8.4) and 6.2 ng/ml (IQR 4.7-10.1) among users and nonusers, respectively (p <0.01). Between those diagnosed in 1996 to 2000 and 2011 to 2016, complementary and alternative medicine use increased 128% from 24% to 54%. When comparing participants diagnosed in 2006 to 2010 with those diagnosed in 2011 to 2016, a 108% increase was seen in supplemental vitamin D use and a -48% decrease was seen in supplemental vitamin E use.

Conclusions: Many patients with prostate cancer reported complementary and alternative medicine use. Multivitamins and omega-3 fatty acids were commonly ingested and vitamin D use increased dramatically from 2006 to 2010 compared to 2011 to 2016. These data can guide clinical discussions and decision making such as nutritionist referral and help prioritize future research.

Citing Articles

Exploring men's cancer journeys in Norway: a comprehensive survey on diet, supplements, and use of complementary and alternative therapies.

Kristoffersen A, Nakandi K, Norheim A, Bjelland M, Nilsen J, Ben-Arye E BMC Complement Med Ther. 2025; 25(1):74.

PMID: 39994718 PMC: 11849388. DOI: 10.1186/s12906-025-04748-7.


Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.

Zhang Y, Stopsack K, Wu K, Song M, Mucci L, Giovannucci E Br J Cancer. 2024; 130(10):1709-1715.

PMID: 38491175 PMC: 11091183. DOI: 10.1038/s41416-024-02651-5.


The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2-A Systematic Review.

Krejbich P, Birringer M Antioxidants (Basel). 2022; 11(11).

PMID: 36358521 PMC: 9686580. DOI: 10.3390/antiox11112149.


Complementary and alternative medicine use among older adults with musculoskeletal pain: findings from the European Social Survey (2014) special module on the social determinants of health.

Morrissey A, ONeill A, OSullivan K, Robinson K Br J Pain. 2022; 16(1):109-118.

PMID: 35111319 PMC: 8801684. DOI: 10.1177/20494637211023293.


Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review.

Kim H, Kim J World J Mens Health. 2022; 40(3):412-424.

PMID: 35021299 PMC: 9253794. DOI: 10.5534/wjmh.210139.


References
1.
Vu D, Molassiotis A, Ching S, Le T . Effects of Qigong on symptom management in cancer patients: A systematic review. Complement Ther Clin Pract. 2017; 29:111-121. DOI: 10.1016/j.ctcp.2017.09.005. View

2.
Goey A, Mooiman K, Beijnen J, Schellens J, Meijerman I . Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev. 2013; 39(7):773-83. DOI: 10.1016/j.ctrv.2012.12.008. View

3.
Skolarus T, Wolf A, Erb N, Brooks D, Rivers B, Underwood 3rd W . American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014; 64(4):225-49. DOI: 10.3322/caac.21234. View

4.
Lyman G, Greenlee H, Bohlke K, Bao T, DeMichele A, Deng G . Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol. 2018; 36(25):2647-2655. DOI: 10.1200/JCO.2018.79.2721. View

5.
Bishop F, Rea A, Lewith H, Chan Y, Saville J, Prescott P . Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. Prostate Cancer Prostatic Dis. 2010; 14(1):1-13. DOI: 10.1038/pcan.2010.38. View